Challenges and Future Trends in the Treatment of Psoriasis

被引:82
作者
Lee, Hyun-Ji [1 ]
Kim, Miri [1 ]
机构
[1] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Dermatol, Seoul 07345, South Korea
关键词
psoriasis; treatment; future trends; SYSTEMIC TREATMENT; MODERATE; SAFETY; METHOTREXATE; MANAGEMENT; BIOLOGICS; DELIVERY; REGISTRY;
D O I
10.3390/ijms241713313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate symptoms and improve quality of life. However, challenges persist, such as adverse effects, treatment resistance, high costs, and variability in response among individuals. The future of psoriasis treatment shows promising emerging trends. New biologic agents targeting novel pathways, such as interleukin 23 inhibitors like mirikizumab, offer enhanced efficacy. Small molecule inhibitors like ROR gamma t inhibitors and ROCK2 inhibitors provide additional treatment options. Combination therapies, including biologics with methotrexate, may improve treatment response. Advancements in topical treatments utilizing microneedles and nanoparticle-based carriers can enhance drug delivery and improve therapeutic outcomes. Biomarkers and multi-omics technologies hold potential for personalized treatment approaches, thus aiding in diagnosis, predicting treatment response, and guiding therapeutic decisions. Collaboration among researchers, clinicians, and industry stakeholders is crucial to translating these scientific breakthroughs into clinical practice. By addressing current challenges and exploring these promising trends, we can optimize psoriasis management and improve the lives of those affected by this chronic condition.
引用
收藏
页数:12
相关论文
共 79 条
  • [1] Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study
    Abdelbary, Aly A.
    AbouGhaly, Mohamed H. H.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 485 (1-2) : 235 - 243
  • [2] Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper
    Ali, Fatima
    Smith, Catherine H.
    Mahil, Satveer K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) : 328 - 329
  • [3] Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review
    Amiri, Diva
    Schwarz, Christopher Willy
    Gether, Lise
    Skov, Lone
    [J]. ACTA DERMATO-VENEREOLOGICA, 2023, 103
  • [4] Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States
    Armstrong, April W.
    Patel, Manish
    Li, Chao
    Garg, Vishvas
    Mandava, Monika Rao
    Wu, Jashin J.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [5] Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
    Armstrong, April W.
    Read, Charlotte
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19): : 1945 - 1960
  • [6] Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis
    Armstrong, April W.
    Puig, Luis
    Joshi, Avani
    Skup, Martha
    Williams, David
    Li, Junlong
    Betts, Keith A.
    Augustin, Matthias
    [J]. JAMA DERMATOLOGY, 2020, 156 (03) : 258 - 269
  • [7] Brodalumab for the treatment of plaque psoriasis: up-to-date
    Beck, Kristen M.
    Koo, John
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (04) : 287 - 292
  • [8] Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis
    Bessar, Hagar
    Venditti, Iole
    Benassi, Luisa
    Vaschieri, Cristina
    Azzoni, Paola
    Pellacani, Giovanni
    Magnoni, Cristina
    Botti, Elisabetta
    Casagrande, Viviana
    Federici, Massimo
    Costanzo, Antonio
    Fontana, Laura
    Testa, Giovanna
    Mostafa, Fawzia Farag
    Ibrahim, Samia Ali
    Russo, Maria Vittoria
    Fratoddi, Ilaria
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 2016, 141 : 141 - 147
  • [9] Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)
    Blauvelt, Andrew
    Kimball, Alexa B.
    Augustin, Matthias
    Okubo, Yukari
    Witte, Michael M.
    Capriles, Claudia Rodriguez
    Sontag, Angelina
    Arora, Vipin
    Osuntokun, Olawale
    Strober, Bruce
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 866 - 877
  • [10] Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
    Blauvelt, Andrew
    Leonardi, Craig L.
    Gooderham, Melinda
    Papp, Kim A.
    Philipp, Sandra
    Wu, Jashin J.
    Igarashi, Atsuyuki
    Flack, Mary
    Geng, Ziqian
    Wu, Tianshuang
    Camez, Anne
    Williams, David
    Langley, Richard G.
    [J]. JAMA DERMATOLOGY, 2020, 156 (06) : 649 - 658